Chemoprophylaxis for tuberculosis and survival of HIV infected patients in Brazil

被引:38
作者
de Pinho, AMF
Santoro-Lopes, G
Harrison, LH
Schechter, M
机构
[1] Univ Fed Rio de Janeiro, Hosp Clementino Fraga Filho, AIDS Res Lab, Infect Dis Serv, BR-21941590 Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Dept Prevent Med, Rio De Janeiro, Brazil
[3] Univ Pittsburgh, Sch Med, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA
关键词
chemoprophylaxis; cohort study; HIV infection; Latin America; prognosis; opportunistic infections; tuberculosis;
D O I
10.1097/00002030-200111090-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To study the impact of chemoprophylaxis for tuberculosis on the survival of HIV-infected patients with a positive tuberculin skin test. Design: Prospective observational cohort study. Setting: Outpatient clinic of a university hospital, in Rio de Janeiro, Brazil. Patients: Two-hundred and ninety-seven patients with a positive tuberculin skin test (reaction greater than or equal to 5mm) who were admitted to the cohort between January 1991 and December 1994. Follow-up ended on September 30, 1998. Intervention: The use of chemoprophylaxis for tuberculosis. Main outcome measures: Death was the primary outcome variable. The occurrence of tuberculosis was studied as a secondary outcome. Cox regression models were used in these analyses. Results: The median follow-up time was 43.6 months. Chemoprophylaxis was used by 128 (43%) of the patients. The use of chemoprophylaxis was associated with a reduction in risk for tuberculosis (hazard ratio, 0.38; 95% confidence interval, 0.14-1.04; P=0.05). In a regression model adjusted for baseline CD4 cell count, chemoprophylaxis was associated with longer survival (hazard ratio, 0.24; 95% confidence interval, 0.09-0.65; P=0.002). Conclusions: Anti-tuberculosis chemoprophylaxis was associated with a substantially prolonged survival among purified protein derivative-positive HIV-infected patients in Brazil. These data have important implications for the clinical care of patients with HIV infection in areas of the world with a high prevalence of Mycobacterium tuberculosis infection. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:2129 / 2135
页数:7
相关论文
共 32 条
[1]   Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials [J].
Bucher, HC ;
Griffith, LE ;
Guyatt, GH ;
Sudre, P ;
Naef, M ;
Sendi, P ;
Battegay, M .
AIDS, 1999, 13 (04) :501-507
[2]  
Centers for Disease Control, 1987, MMWR-MORBID MORTAL W, V36, p1S
[3]   TUBERCULOSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - CLINICAL-FEATURES, RESPONSE TO THERAPY, AND SURVIVAL [J].
CHAISSON, RE ;
SCHECTER, GF ;
THEUER, CP ;
RUTHERFORD, GW ;
ECHENBERG, DF ;
HOPEWELL, PC .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (03) :570-574
[4]   AN OUTBREAK OF TUBERCULOSIS WITH ACCELERATED PROGRESSION AMONG PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS - AN ANALYSIS USING RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS [J].
DALEY, CL ;
SMALL, PM ;
SCHECTER, GF ;
SCHOOLNIK, GK ;
MCADAM, RA ;
JACOBS, WR ;
HOPEWELL, PC .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (04) :231-235
[5]   Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology [J].
Del Amo, J ;
Malin, AS ;
Pozniak, A ;
De Cock, KM .
AIDS, 1999, 13 (10) :1151-1158
[6]   Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection [J].
Girardi, E ;
Antonucci, G ;
Vanacore, P ;
Libanore, M ;
Errante, I ;
Matteelli, A ;
Ippolito, G .
AIDS, 2000, 14 (13) :1985-1991
[7]  
Goletti D, 1996, J IMMUNOL, V157, P1271
[8]   Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease [J].
Graham, NMH ;
Galai, N ;
Nelson, KE ;
Astemborski, J ;
Bonds, M ;
Rizzo, RT ;
Sheeley, L ;
Vlahov, D .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (08) :889-894
[9]   Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: Results of a randomized controlled trial [J].
Hawken, MP ;
Meme, HK ;
Elliott, LC ;
Chakaya, JM ;
Morris, JS ;
Githui, WA ;
Juma, ES ;
Odhiambo, JA ;
Thiongo, LN ;
Kimari, JN ;
Ngugi, EN ;
Bwayo, JJ ;
Gilks, CF ;
Plummer, FA ;
Porter, JDH ;
Nunn, PP ;
McAdam, PWJ .
AIDS, 1997, 11 (07) :875-882
[10]   Decline in deaths from AIDS due to new antiretrovirals [J].
Hogg, RS ;
OShaughnessy, MV ;
Gataric, N ;
Yip, B ;
Craib, K ;
Schechter, MT ;
Montaner, JSG .
LANCET, 1997, 349 (9061) :1294-1294